You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽託生物(300583.SZ)2020年業績轉虧 預虧1.32億元-1.71億元
格隆匯 01-22 16:03

格隆匯1月22日丨賽託生物(300583.SZ)披露2020年度業績預吿,公司預計2020年度實現歸屬於上市公司股東的淨利潤為虧損1.32億元至1.71億元,而上年同期為盈利5530.95萬元。業績變動原因説明:

1、報吿期,受新冠肺炎疫情影響,公司為適應市場競爭和行業格局變化,確保細分行業龍頭地位,階段性調整產品銷售結構及銷售價格,毛利率水平短期有所下降,全年銷售收入減少。

2、報吿期,公司為儲備的產品未來規模化生產,對原有廠房及生產線進行改造致使部分設備拆除閒置或不再具備使用價值,該類固定資產存在減值跡象;海外疫情形勢難以預測,收購意大利Lisapharma公司形成的商譽存在減值跡象;受生產技術革新影響,公司部分無形資產-非專利技術存在減值跡象。基於謹慎性原則,公司將對上述資產計提資產減值準備共計7000萬元至9000萬元。最終減值準備計提金額將由審計機構進行審計後確定。

3、報吿期,子公司Lisapharma公司全年納入公司合併範圍,子公司潤鑫熱力12月份投產,未投產期間固定資產折舊計入管理費用,導致整體費用較上年同期增加。

4、報吿期,為實現公司“醫藥中間體、原料藥、製劑”一體化的產業鏈升級的中長期戰略目標,公司持續研發投入,加強人才儲備,同時在安全環保領域持續投入,導致公司相關費用較同期有所增加。

5、報吿期,預計非經常性損益對公司淨利潤的影響金額約為1678.20萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account